Sonki, you're right, see the bolded sentence from the following paragraph in their PR newswire:
"In the past," he continued, "we noted that we were comfortable with the
range of the majority of analysts' diluted earnings-per-share estimates of
$2.05 to $2.10 for the year, excluding the impacts of acquisitions,
divestitures, licensing fees, legal settlements and other unusual and non-
recurring items. The divestiture of the MTG businesses (with earnings
expected at about 10 cents per share on a full-year basis) now indicates a
range of $1.95 to $2.00 per share for the full year from continuing
operations, excluding unusual and non-recurring items, with which we remain
comfortable. Moving forward, we expect that our strengthened commercial
infrastructure, our strong and broad product line, global presence,
technological sophistication and our sharp focus on the numerous opportunities
in the pharmaceutical business will lead to significantly more rapid revenue
growth, and strong improvements in profitability and return on investment."
moneynet.com@NEWS-P1&Index=1&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company |
